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Abstract
BACKGROUND: In evaluating uterine cervical cancer with 18F-fluorodeoxyglucose (FDG) positron emission tomography/com-
puted tomography (PET/CT), there may be overlap between the FDG activity at tumor sites and nonspecific radioactivity in the 
urine. We evaluated the efficacy of furosemide premedication with routine hydration to obtain better contrast and less overlap 
between cervical cancer and the urinary bladder.
MATERIAL AND METHODS: We retrospectively evaluated 166 patients who had primary or relapsed cervical cancer and 
underwent FDG PET/CT scanning with (133 patients) or without (33 patients) furosemide premedication (10 mg intravenous, 
slowly injected 30 min before the scan). We calculated bladder and tumor maximum and median standardized uptake value 
(SUVmax and SUVmed), and overlap between tumor and urinary activity was detected visually.
RESULTS: Overlap between urinary and tumor radioactivity was observed in 8 of 133 scans (6%) in patients who receive furosemide 
and in 3 of 33 scans (9%) in patients who did not receive furosemide. The SUVmax and SUVmed for the bladder were significantly 
lower in patients who were pretreated with furosemide (SUVmax, 6.3; SUVmed, 4.6) than patients who were not pretreated with furo-
semide (SUVmax, 8.8 [P ≤ 0.008]; SUVmed, 6.5 [P ≤ 0.002]). The tumor SUVmax and SUVmed were similar between the patient groups.
CONCLUSION: Furosemide premedication before FDG PET/CT scanning may enable improved evaluation of activity and 
extension of cervical cancer.
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Background
Patients who have early cervical cancer can be treated with 
surgery or radiotherapy, but women who have more advanced cervi-
cal tumors that are metastatic to lymph nodes or pelvic tissues are 
treated usually with a combination of external beam radiotherapy 
and intracavitary brachytherapy. Evaluation with positron emission 
tomography/computed tomography (PET/CT) with the glucose ana-
logue 18F-fluorodeoxyglucose (FDG) may facilitate tumor detection, 
staging, restaging after radical therapy, prognostic assessment, 
and radiotherapy planning [1–4].
The major source of uncertainty in the interpretation of PET/CT im-
ages is the anatomic position of the uterine cervix contiguous with the 
urinary bladder. Unlike glucose, FDG is not completely reabsorbed in 
the kidneys, and a variable amount of radioactivity may be found in 
the urinary tract after FDG injection. Therefore, there may be overlap 
between the FDG activity at tumor sites and nonspecific radioactivity 
in the urine. In 15 PET/CT centers, routine bladder catheterization usu-
ally is not performed before scanning [5]. An alternative noninvasive 
way to decrease urine radioactivity is highly desirable.
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Better contrast between tumor FDG uptake and urine radio-
activity may be achieved by decreasing urine radioactivity with 
standardized patient hydration protocols or the administration of 
diuretic drugs before PET/CT scanning [6–7]. The European As-
sociation of Nuclear Medicine guidelines suggest hydration and 
diuretic administration during the investigation of small pelvic 
tumors [8].
We hypothesized that the diuretic furosemide may improve 
contrast between cervical cancer and the urinary bladder during 
PET/CT scanning. The purpose of the present study was to evaluate 
the efficacy of using furosemide with routine hydration to obtain 
better contrast and less overlap between cervical cancer and the 
urinary bladder.
Materials and methods
Subjects
We retrospectively evaluated 166 patients who had primary 
or relapsed cervical cancer and who underwent FDG PET/CT 
scan at our center between December 2011 and November 2012. 
The scans were performed in accordance with current guide-
lines including intravenous injection of 18F-FDG (185 to 444 
MBq) at 1 hour before image acquisition [7]. The PET/CT scan 
was performed with 2 scanners (72 patients: Philips Gemini 
GXL16 scanner, Philips Healthcare, Andover, MA, USA; 94 patients: 
Siemens Biograph mCT128 scanner, Siemens, Malvern, PA, USA). 
The cross-calibration process was performed on a regular basis to 
ensure measurement stability between different scanners. 
Procedures
All patients were routinely instructed to drink ≥ 1 L of water within 
2 hours before the examination and to void just before image acqui-
sition. Patients were divided into 2 groups: patients who received 
premedication with furosemide (10 mg intravenous, slowly injected 
30 min before the scan; 133 patients [80%]), and patients who did 
not receive furosemide because of a history of furosemide hyper-
sensitivity, kidney stones, or renal colic (33 patients [20%]). No 
patient who was treated with furosemide had adverse events from 
diuretic administration. The maximum and median standardized 
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uptake value (SUVmax and SUVmed) for the bladder and tumor were 
determined for each patient in both groups by manually drawing 
the free region of interest. Visual analysis was performed indepen-
dently by 2 nuclear medicine specialists with software (Syngovia 
v.1.1.0.17, Siemens AG, Munich, Germany) to identify patients who 
had overlap between urinary and tumor activity.
Data analysis
Data analysis was performed with statistical software (STA-
TISTICA v10.0, StatSoft, Tulsa, OK, USA). Normality of distribution 
was tested with Shapiro-Wilk test for SUVmax and SUVmed for the 
bladder and tumor for both patient groups; only the SUVmax and 
SUVmed for the tumor in patients who received furosemide were 
normally distributed. The basic statistics such as median, mini-
mum, maximum, and interquartile range were calculated for each 
of the considered variables. The Mann-Whitney test was used for 
comparisons between the groups, because the groups were un-
related, the data were quantitative, and the data lacked normality. 
The primary outcome of the study was to compare the SUVmax and 
SUVmed for the bladder and tumor between the 2 patient groups. 
The null hypothesis assumed that the median values of these vari-
ables were equal. Statistical significance was defined by P ≤ 0.05.
Results
Overlap between urine and tumor radioactivity was observed 
in 8 of 133 scans (6%) in patients who received furosemide and 
in 3 of 33 scans (9%) in patients who did not receive furosemide 
(Figure 1 and 2). The bladder SUVmax and SUVmed were significantly 
lower in patients who were pretreated than in those who were not 
pretreated with furosemide (Table 1). The tumor SUVmax and SUVmed 
were similar between the patient groups (Table 1).
Discussion
The present result showed that SUVmax and SUVmed of the blad-
der, but not tumor, were significantly lower in patients who were 
pretreated than in those who were not pretreated with furosemide 
(Table 1). This suggests that pretreatment with furosemide may be 
Figure 1. Transverse and sagittal fused 18F-fluorodeoxyglucose positron emission tomography/computed tomography scan in a patient who had 
cervical cancer stage IVA with infiltration of the bladder wall. The patient received furosemide before the scan. Furosemide premedication reduced 
urinary radioactivity and enabled good visualization of the neoplasm (A, B)
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helpful in minimizing overlap between the FDG activity at tumor 
sites and nonspecific radioactivity in the urine. 
Nonspecific accumulation of FDG in the urinary tract may 
interfere with the visualization of pelvic and retroperitoneal abnor-
malities in a PET/CT scan. In the current literature, difficulties in 
images interpretation were reported in a significant percentage of 
patients, most frequently patients who had colorectal or ovarian 
cancers [9, 10]. This is an important issue, especially for pa-
tients with pelvic malignancies who are referred for PET/CT scan 
for radiotherapy planning. Bladder catheterization is effective but 
it is invasive and may cause urinary tract infection [11]. In addition, 
bladder catheterization is time-consuming and difficult in clinical 
settings that have tightly scheduled examinations. Studies about the 
efficacy of furosemide premedication before PET/CT scanning have 
been performed for abdominal, bladder, and colorectal cancers, 
but only occasionally for cervical cancer [10–17].
The timing of diuretic injection is an important issue in order to 
obtain an optimal distinction between tumor and bladder [6]. In our 
experience, most patients had difficulties in holding back urination 
for > 30 minutes after furosemide intravenous injection. 
Statistical analysis of tumor activity showed no difference be-
tween patients who had or did not have furosemide premedication 
(Table 1). The significantly lower bladder radioactivity for patients 
who received furosemide pretreatment (Table 1) is evidence that 
increased urine production effectively reduce tracer concentration 
in the urinary tract. These data correlate with a higher ratio of overlap 
between urine and tumor images on the PET/CT scan in patients who 
did not receive furosemide that can hinder the delineation of tumor 
borders. This is important for the use of PET/CT scanning in planning 
cervical cancer radiotherapy. Adaptive radiotherapy strategies have 
been proposed to minimize the effect of possible changes in cervix 
position because varied bladder volumes may cause displacement of 
pelvic organs. It is possible to measure cervical displacement by com-
paring pretreatment CT scans with full and empty bladder [18, 19]. 
Modulated adaptive radiotherapy may be coupled with furosemide 
premedication to improve the quality of PET/CT images and accu-
rately measure cervical displacement.
The findings in this report are subject to at least two limita-
tions. First, the sample size of control group is relatively small. 
Furthermore, comparison with a control group of catheterized 
patients was not carried out. 
Table 1. Standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans in patients who had 
cervical cancer*
Parameter With furosemide Without furosemide P ≤ †
Median (Minimum to maximum) [Interquartile range] Median (Minimum to maximum) [Interquartile range]
No. patients 133 33
Bladder SUVmax 6.3 (3.0–24.7) [5.0–8.0] 8.8 (3.0–31.9) [6.4–10.2] 0.008
Bladder SUVmed 4.6 (1.9–15.4) [3.8–5.8] 6.5 (2.6–19.8) [4.6–8.3] 0.002
Tumor SUVmax 15.4 (3.7–31.7) [10.6–20.4] 14.6 (5.7–43.6) [10.7–19.1] NS
Tumor SUVmed 7.6 (2.0–16.6) [5.9–9.7] 7.9 (2.9–29.0) [6.0–10.1] NS
*N = 166 patients. Data reported as number or median (range, minimum to maximum) [interquartile range]. Abbreviations: SUVmax — maximum standardized uptake value; SUVmed — median 
standardized uptake value. †NS — not significant (P > 0.05)
Figure 2. Transverse and sagittal fused 18F-fluorodeoxyglucose positron emission tomography/computed tomography scan in a patient who had 
cervical cancer stage IVA with infiltration of the bladder wall. The patient did not receive furosemide before the scan. Overlap of radioactivity was 
observed between the bladder and the cancer
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Table 2. Overlap between urinary and tumor radioactivity in patients 
with and without furosemide premedication 
Group Number of 
patients
Patient with 
overlap (%)
With furosemide premedication 133 8 (6%)
Without furosemide premedication 33 3 (9%)
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In summary, the present study shows that a combination of 
hydration and furosemide premedication may enable better evalu-
ation of cervical cancer anatomy on PET/CT imaging. The present 
protocol potentially may be used in planning adaptive radiotherapy.
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